HEPZATO KIT

Delcath Systems, Inc. announced preliminary Q3 2025 results, with total CHEMOSAT and HEPZATO KIT revenue reaching $20.5 million and net income at $0.8 million. The company projects full-year revenue between $83 and $85 million, representing a 150% treatment volume increase. Positive adjusted EBITDA and operating cash flow are anticipated for each quarter of 2025. A conference call is scheduled for October 20 to discuss results and the CHOPIN trial. The company focuses on liver cancer therapies, including HEPZATO KIT and CHEMOSAT.